Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,143.2
-16.4 (-0.52%)

 

  • STI Straits Times Index
    3,143.2
    -16.4 (-0.52%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,592.9
    -4.5 (-0.28%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,222.4
    -213.3 (-0.81%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,977.1
    -29.4 (-0.98%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,079.1
    34.6 (0.16%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,206.2
    -25.3 (-0.41%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,091.7
    0.2 (0.01%)
    Index delayed 20 minutes
  • XAO XAO
    6,861.1
    22.1 (0.32%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 567.5M
  • Value: 763.1M
  • Rise: 102
  • Fall: 189
  • Unch: 545

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
BHG Retail Reit0.680-
Rex Intl0.082-0.002
Mapletree Com Tr2.290+0.020
YZJ Shipbldg SGD1.010+0.010
Keppel DC Reit1.960-0.150
Nam Cheong0.006-0.002
JCG Investment0.002-
Genting Sing0.890-0.015
SingPost0.970+0.025
Mapletree Ind Tr2.470-0.020

World Indices

World Indices
Name Last Change
Nasdaq 8,117.7 -65.2
HSI 26,222.4 -213.3
HSCEI 10,287.9 -87.7
Jakarta 6,206.2 -25.3
Nikkei 225 22,079.1 +34.6
SSE Comp 2,977.1 -29.4
Shanghai A 3,118.8 -30.8
Shanghai B 273.1 -0.3
PSE Comp 0.0
KOSPI 2,091.7 +0.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

DPHARMA DUOPHARMA BIOTECH BERHAD
Quotes 15 Minutes Delayed. Updated at 23 Sep 2019 16:53
Last (MYR): 1.390 Change: -0.010 High: 1.410 Remarks: s
Remarks legend:
RemarksDescriptionRemarksDescription
IOrder entry forbiddenAOrder entry authorized
GFrozenSSuspended
RReservedsShort selling available
[x]Exclude dividend[c] Cum dividend
Change (%): -0.71 Low: 1.390
Open 1.410 Yesterday's Close 1.400
Buy Price 1.390 Sell Price 1.400
Buy Volume ('00) 92 Sell Volume ('00) 275
Cumulative Volume ('00) 807 Cumulative Value 113,318
Click to show Stock Prices chart

Latest News

View All News

Key Statistics

EPS (MYR) a 0.07005 Trailing EPS (MYR) e 0.08092 NAV (MYR) b 0.7407
PE a 19.843 Trailing PE f 17.177 Price / NAV b 1.8766
Dividend (MYR) d 0.053526 Cash In Hand (MYR) g 0.1414 Issued & Paid-up Shares c 680,106,000
Dividend Yield (%) d 3.851 Price / Cash In Hand g 9.830 Treasury Shares h -
Beta - 75 Daysi 0.695 R-Squared - 75 Days(%)i 5.42 Market Cap (M) 945.347
Beta - 500 Daysi 0.899 R-Squared - 500 Days (%)i 7.95 Enterprise Value (M) 1,110.222
Piotroski F Score 6 Exchange Code 7148 Par Value ( MYR ) 0.50000
52 Weeks Volatility (%) 27.06 6-Month VWAP 1.352 Free Float (%) 42.8
Shariah Compliant Stocks Yes
Sector & Industry Health Technology - Biotechnology
Index Components BM HEALTH CARE
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 29 Jul 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference DPHARMA Bursa 945.347 19.843 17.177 1.8766 3.851
Industry Biotechnology Bursa 332.854 22.264 19.270 1.7003 3.646
PHARMACEUTICALS Bursa 487.911 15.934 15.549 1.7044 3.121
Index BM HEALTH CARE Bursa 7,343.366 44.578 44.311 2.8159 1.075
Local Peer MGRC Bursa 26.913 - - 1.6894 -
Local Peer MEGASUN Bursa 26.302 25.120 42.286 0.3889 -
Global Peer AMGEN INC NASDAQ 118,105.115 14.070 14.841 10.9417 2.815
Global Peer GILEAD SCIENCES INC NASDAQ 84,117.609 15.420 14.126 3.7194 3.475
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 107,422.703 40.039 40.039 14.3553 1.121
Global Peer CELGENE CORP NASDAQ 70,427.593 17.407 13.361 7.0070 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 45,783.074 21.839 20.670 9.0303 -
Global Peer ILLUMINA INC NASDAQ 45,506.790 55.093 48.515 10.5048 -
Global Peer BIOGEN INC NASDAQ 44,044.099 9.941 8.319 3.4003 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,514.441 13.302 15.713 3.3328 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 24,129.220 76.358 22.509 5.0831 0.785
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), BIO-TECHNE CORP (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), REPLIGEN CORP (NASDAQ), 3SBIO (HKEx), ALLOGENE THERAPEUTICS INC (NASDAQ), GENSCRIPT BIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), XENCOR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INSMED INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), CARA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), EPIZYME INC (NASDAQ), POLYNOVO LIMITED (ASX), DICERNA PHARMACEUTICALS INC. (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), VIVA BIOTECH (HKEx), OMEROS CORP (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), CORTEXYME INC (NASDAQ), HAOHAI BIOTEC (HKEx), ZIOPHARM ONCOLOGY INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), VOYAGER THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), SYNTHORX INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), RETROPHIN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), AKEBIA THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), PERSONALIS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MERUS B V (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), CKLIFE SCIENCES (HKEx), CHEMOCENTRYX INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), AGENUS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), XBIOTECH INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ESSEX BIO-TECH (HKEx), KADMON HLDGS INC (NYSE), PROTAGONIST THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), NEXT SCIENCE LTD (ASX), RESTORBIO INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), MEDICINOVA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), LEE'S PHARM (HKEx), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ARDELYX INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PIERIS PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), GERON CORP (NASDAQ), RECRO PHARMA INC (NASDAQ), TELIX PHARMACEUTIC (ASX), CLOVIS ONCOLOGY INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), PDL BIOPHARMA INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), XENON PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), AFFIMED N V (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), KAMADA (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PFENEX INC (NYSE American), CUE BIOPHARMA INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), XOMA CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), IMV INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), AVEO PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), BBI LIFE SCI (HKEx), CHIMERIX INC (NASDAQ), UNI-BIO GROUP (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), SESEN BIO INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VACCINEX INC (NASDAQ), SAVARA INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), VERASTEM INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ADURO BIOTECH INC (NASDAQ), ARAVIVE INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), ARBUTUS BIOPHARMA CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), TREVENA INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SYNLOGIC INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CEL-SCI CORP (NYSE American), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PHYLOGICA LIMITED (ASX), INFLARX N V (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), PORT (SET), NEON THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), INMUNE BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), COHBAR INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), IMUGENE LIMITED (ASX), IBIO INC (NYSE American), UNUM THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), VERMILLION INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), CT ENTERPRISE (HKEx), CIDARA THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), IVERIC BIO INC (NASDAQ), REGENT PACIFIC (HKEx), EVOGENE LTD (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ORTHOCELL LIMITED (ASX), CELLDEX THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIOCARDIA INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ZAFGEN INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), FIBROCELL SCIENCE INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), BIOTRON (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), EXTRAWELL PHAR (HKEx), AZURRX BIOPHARMA INC (NASDAQ), BIOSINO BIO-TEC (HKEx), ORAGENICS INC (NYSE American), RHINOMED LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), HISTOGENICS CORP (NASDAQ), MEMPHASYS LTD (ASX), BIOCEPT INC (NASDAQ), ISORAY INC (NYSE American), SOLIGENIX INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), NOVELION THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), TOCAGEN INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), BIONOMICS LTD (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PATRYS LIMITED (ASX), ADALTA LTD (ASX), ATYR PHARMA INC (NASDAQ), PRECIPIO INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), Suntar Eco-City^ (SGX), IMMURON LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), CELLMID LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), NANOVIRICIDES INC (NYSE American), ENDRA LIFE SCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES (ASX), TROVAGENE INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), BIOXYNE LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), REXAHN PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), BIONANO GENOMICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), HAO WEN HLDGS (HKEx), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), MEDIBIO LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADVAXIS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), OPGEN INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), QT Vascular (SGX), NOVITA HEALTHCARE LTD (ASX), SPHERIX INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), TBG DIAGNOSTICS LTD (ASX), CCP TECHNOLOGIES LTD (ASX), NEURALSTEM INC (NASDAQ), NANOLLOSE LTD (ASX), BPH ENERGY LIMITED (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.030
+2.21 %
10 Days -+0.020
+1.46 %
20 Days --0.020
-1.42 %
Medium Term Return 3 Months 0.040+0.020
+4.38 %
6 Months 0.040+0.190
+19.17 %
1 Year 0.055+0.200
+21.43 %
Long Term Return 2 Years 0.140+0.413
+56.60 %
3 Years 0.205+0.529
+85.25 %
5 Years 0.485+0.325
+76.06 %
Annualised Return Annualised --
+11.98 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.925 - 1.480 Change From 1 Year Low +0.465 % Change From 1 Year Low (%) +50.27
Change From 1 Year High -0.090 % Change From 1 Year High (%) -6.08
2 Years Range 0.883 - 1.490 Change From 2 Years Low +0.507 % Change From 2 Years Low (%) +57.44
Change From 2 Years High -0.100 % Change From 2 Years High (%) -6.71
5 Years Range 0.814 - 1.490 Change From 5 Years Low +0.576 % Change From 5 Years Low (%) +70.70
Change From 5 Years High -0.100 % Change From 5 Years High (%) -6.71
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CCM Duopharma Biotech Berhad, an investment holding company, engages in the manufacture, distribution, import, and export of pharmaceutical products and medicines in Malaysia. It offers various over the counter products, including analgesic/anti-pyretics, antibacterial mouthwash, childrens vitamins, cough preparations, dermatology products, eye drops, first aid dressings, and health suppliments. The company provides its products in various forms, such as tablets, capsules, syrup, oral antibiotic, creams, haemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges, and eye drop preparations. It exports its products to various countries, including Vietnam, Ethiopia, Sudan, South East Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Republic of Yemen, Singapore, and Hong Kong. The company was founded in 1979 and is based in Klang, Malaysia. CCM Duopharma Biotech Berhad is a subsidiary of CCM Marketing Sdn. Bhd.

IPO Performance

Listing Date 18 Jul 2002 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) 7.50 Public Offer Subscription Rate (x) -
IPO Price (MYR) 2.100 First Day Close (MYR) 1.043 First Week Close (MYR) 1.006
Current vs IPO Price (%) -33.81 First Day Gain (%) -50.33 First Week Gain (%) -52.10

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(2.61 MB)
Part 2(2.17 MB)
Annual Report 2018 Apr 2018 Part 1(1.46 MB)
Part 2(0.88 MB)
Part 3(0.27 MB)
Part 4(2.43 MB)
Part 5(1.63 MB)
Annual Report 2016 Dec 2016 Part 1(2.85 MB)
Part 2(0.73 MB)
Annual Report 2015 Dec 2015 Part 1(0.08 MB)
Part 2(2.44 MB)
Part 3(0.02 MB)
Part 4(0.04 MB)
Annual Report 2014 Dec 2014 Part 1(2.20 MB)
Annual Report 2013 Dec 2013 Part 1(1.34 MB)
Annual Report 2012 Dec 2012 Part 1(1.64 MB)
Annual Report 2011 Dec 2011 Part 1(1.12 MB)
Part 2(0.11 MB)
Annual Report 2010 Dec 2010 Part 1(2.37 MB)
Annual Report 2009 Dec 2009 Part 1(2.87 MB)
Part 2(0.15 MB)
Annual Report 2008 Dec 2008 Part 1(0.82 MB)
Annual Report 2007 Dec 2007 Part 1(0.04 MB)
Part 2(2.16 MB)
Annual Report 2006 Dec 2006 Part 1(1.01 MB)
Part 2(0.02 MB)
Annual Report 2005 Dec 2005 Part 1(0.30 MB)
Part 2(0.82 MB)
Annual Report 2004 Dec 2004 Part 1(0.52 MB)
Part 2(1.35 MB)
Annual Report 2003 Dec 2003 Part 1(0.63 MB)
Annual Report 2002 Dec 2002 Part 1(1.12 MB)
Part 2(0.42 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
23 Sep 2019 1.410 1.410 1.390 1.390 80,700 1.4042
20 Sep 2019 1.360 1.450 1.360 1.400 2,484,300 1.4076
19 Sep 2019 1.350 1.370 1.340 1.350 720,400 1.3515
18 Sep 2019 1.340 1.350 1.330 1.340 1,529,000 1.3412
17 Sep 2019 1.370 1.370 1.330 1.330 1,502,000 1.3403
13 Sep 2019 1.390 1.390 1.360 1.360 1,678,400 1.3708
12 Sep 2019 1.400 1.400 1.380 1.380 1,115,100 1.3888
11 Sep 2019 1.400 1.410 1.370 1.390 964,500 1.3857
10 Sep 2019 1.370 1.400 1.360 1.380 1,079,500 1.3829
06 Sep 2019 1.410 1.410 1.370 1.370 368,300 1.3897
05 Sep 2019 1.410 1.410 1.400 1.400 890,300 1.4001
04 Sep 2019 1.380 1.420 1.380 1.410 508,800 1.4089
03 Sep 2019 1.410 1.440 1.390 1.410 460,400 1.4083
30 Aug 2019 1.440 1.450 1.400 1.410 373,700 1.4150
29 Aug 2019 1.400 1.470 1.400 1.420 512,000 1.4319
28 Aug 2019 1.410 1.430 1.380 1.410 1,251,400 1.4013
27 Aug 2019 1.400 1.430 1.400 1.410 1,023,200 1.4115
26 Aug 2019 1.440 1.440 1.390 1.410 693,600 1.4096
23 Aug 2019 1.400 1.480 1.390 1.450 1,233,700 1.4485
22 Aug 2019 1.350 1.410 1.350 1.400 690,400 1.3954
21 Aug 2019 1.340 1.370 1.330 1.360 517,300 1.3501
20 Aug 2019 1.320 1.340 1.320 1.330 11,900 1.3327
Summary
Current 2 Weeks
(06 Sep 2019 to 23 Sep 2019)
1.410 1.450 1.330 1.390 11,522,200 -
Previous 2 Weeks
(22 Aug 2019 to 05 Sep 2019)
1.350 1.450 1.330 1.400 7,637,500 -
4 Weeks from
(23 Jul 2019 to 21 Aug 2019)
1.380 1.450 1.330 1.360 11,432,900 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.